BRIEF published on 09/15/2026 at 15:40, 1 month 25 days ago Revive Therapeutics vise à élargir son portefeuille de produits à base de bucillamine. Propriété Intellectuelle Maladies Orphelines Contre-mesures Médicales Bucillamine Partenariats Gouvernementaux
BRIEF published on 09/15/2026 at 15:40, 1 month 25 days ago Revive Therapeutics Aims to Expand Bucillamine Portfolio Intellectual Property Orphan Diseases Medical Countermeasures Government Partnerships Bucillamine
PRESS RELEASE published on 09/15/2026 at 15:35, 1 month 25 days ago Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases Revive Therapeutics Ltd. outlines strategy to build protected bucillamine franchise for medical countermeasures, rare diseases, and government preparedness programs Rare Diseases Medical Countermeasures Revive Therapeutics Ltd. Bucillamine Franchise Government Preparedness
BRIEF published on 08/19/2026 at 20:40, 2 months 22 days ago Revive Therapeutics Proposes Shares for Debt Settlement Debt Settlement Canadian Securities Exchange Shares Issuance Revive Therapeutics Biodefense Research
BRIEF published on 08/19/2026 at 20:40, 2 months 22 days ago Revive Therapeutics propose des actions en échange du règlement de sa dette Émission D'actions Règlement De Dettes Bourse Canadienne Des Valeurs Mobilières Revive Therapeutics Recherche En Biodéfense
PRESS RELEASE published on 08/19/2026 at 20:35, 2 months 22 days ago Revive Therapeutics Announces Proposed Shares for Debt Settlement Revive Therapeutics Ltd. announces proposed debt settlement by issuing Settlement Shares to settle outstanding trade payables. Subject to CSE approval Debt Settlement Settlement Shares CSE Approval Revive Therapeutics Ltd. Biodefence
BRIEF published on 08/19/2026 at 14:45, 2 months 22 days ago Revive Therapeutics fait progresser sa stratégie de biodéfense avec la bucillamine Biodefense Contre-mesures Médicales Préparation Aux Pandémies Bucillamine Partenariats Gouvernementaux
BRIEF published on 08/19/2026 at 14:45, 2 months 22 days ago Revive Therapeutics Advances Biodefence Strategy with Bucillamine Medical Countermeasures Pandemic Preparedness Government Partnerships Bucillamine Biodefence
PRESS RELEASE published on 08/19/2026 at 14:40, 2 months 22 days ago Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio Revive plans to expand bucillamine use in biodefence with positive DRDC findings, government opportunities, and complementary therapies, focusing on medical countermeasures Bucillamine Biodefence Revive DRDC Government Opportunities
BRIEF published on 08/15/2026 at 00:55, 2 months 27 days ago Revive Therapeutics Grants 15.5 Million Stock Options Stock Options Life Sciences Biodefense Pandemic Preparedness Revive Therapeutics
Published on 11/11/2026 at 03:30, 5 hours 28 minutes ago CoTec Holdings Corp. Files Third Quarter Financial Statements and MD&A and Provides Market Commentary
Published on 11/11/2026 at 00:40, 8 hours 18 minutes ago Upgraded Tunkillia MRE Validates Optimised Scoping Study
Published on 11/10/2026 at 23:30, 9 hours 28 minutes ago CCL Industries Announces 2026 Third Quarter Results
Published on 11/10/2026 at 23:00, 9 hours 58 minutes ago Vanta Announces Appointment of Chief Financial Officer and Corporate Secretary
Published on 11/10/2026 at 23:00, 9 hours 58 minutes ago Battery X Metals Announces Appointment of Chief Financial Officer and Corporate Secretary
Published on 11/11/2026 at 08:31, 27 minutes ago Delivery Hero SE: Notice to the Bondholders of the EUR 500 million Convertible Bonds due 2029 (ISIN DE000A3MP437 – Common Code 238511097 – German Securities Code (WKN) A3MP43)
Published on 11/11/2026 at 08:30, 27 minutes ago Delivery Hero SE: Notice to the Bondholders of the EUR 1,000 million Convertible Bonds due 2030 (ISIN DE000A30V5R1 – Common Code 258943848 – German Securities Code (WKN) A30V5R)
Published on 11/11/2026 at 08:30, 28 minutes ago Delivery Hero SE: Notice to the Bondholders of the EUR 750 million Convertible Bonds due 2028 (ISIN DE000A3H2WQ0 – Common Code 220637387 – German Securities Code (WKN) A3H2WQ)
Published on 11/11/2026 at 08:30, 28 minutes ago aap Implantate AG: Management Board refines 2026 forecast and provides first outlook for 2027 – Ambition 2030: Revenue of at least EUR 21 million with an EBITDA margin of 17.5% to 22.5%
Published on 11/11/2026 at 08:30, 28 minutes ago Delivery Hero SE: Notice to the Bondholders of the EUR 875 million Convertible Bonds due 2027 (ISIN DE000A254Y92 – Common Code 210751831 – German Securities Code (WKN) A254Y9)
Published on 11/10/2026 at 18:00, 14 hours 58 minutes ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 15 hours 13 minutes ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 15 hours 23 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 15 hours 26 minutes ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
